SHIONOGI & CO., LTD.

Symproic® (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan

Osaka, Japan (March 30, 2017) - Shionogi & Co., Ltd. (hereafter "Shionogi") announced that Symproic® (generic name: naldemedine tosilate) was approved today by the Ministry of Health, Labor and Welfare for the treatment of opioid-induced constipation (OIC).

Symproic® is a peripherally-acting mu-opioid receptor antagonist (PAMORA) that has been developed by Shionogi as a once-daily treatment of OIC. Symproic® is expected to be a new treatment option that can improve the quality of life in patients with OIC in pain management with opioid analgesics.

'Symproic®' Product Description

Product Name	Symproic® Tablets 0.2mg
Generic Name	naldemedine tosilate
Indication	Opioid-Induced Constipation
Dosage and Administration	The usual adult dosage for oral use is 0.2 mg of naldemedine once daily.
Approval Date	March 30, 2017

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and well-being of the patients we serve." Shionogi's research and development currently targets two therapeutic areas: infectious diseases and pain/CNS disorders. A 139 year old company, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives for over 50 years. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit http://www.shionogi.co.jp/en/.

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing

products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contacts:

Corporate Communications, Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596

# # #